Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma.
PMID 19789534 · PMC2768081 · British journal of cancer · 2009 · 8 claims · 7 setups
Cathepsin D, identified via comparative 2D PAGE of conditioned media from RCC cell lines vs normal renal cultures, is a candidate secreted biomarker of RCC
-
Full-text index only
Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.
PMID 15601541 · PMC3525069 · Human genomics · 2004 · 8 claims · 6 setups
DNA microarray gene expression profiling generates robust molecular classifications for many tumour types (brain, breast, colon, gastric, kidney, leukaemia, lymphoma, lung, melanoma, ovary, prostate, etc.)
-
Full-text index only
CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.
PMID 16892042 · PMC2360640 · British journal of cancer · 2006 · 6 claims · 6 setups
CD70 was identified by proteomic analysis of plasma membrane preparations as highly expressed in A498 and SW839 RCC-derived cell lines
-
Full-text index only
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.
PMID 18397877 · PMC2427143 · Human molecular genetics · 2008 · 8 claims · 8 setups
All six somatic TSC1 missense mutations found in bladder tumours cause loss of TSC1 function, but via distinct molecular mechanisms.
-
Full-text index only
Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
PMID 18212748 · PMC2243141 · British journal of cancer · 2008 · 5 claims · 6 setups
LC-MS/MS proteomic analysis of stage I lung adenocarcinoma specimens identified myosin IIA and vimentin as candidate biomarker proteins with signal intensities that differed significantly among patient outcome groups